Patient-Centered Treatment Strategies in the Management of nAMD and DME

Recently approved anti-VEGF agents that target additional pathways and offer innovative delivery methods with longer-lasting effects may provide advantages over older anti-VEGF agents in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this podcast, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.